Lancashire and South Cumbria
Formulary
Formulary
1 Gastro-intestinal system
01-04-02 Antimotility drugs
| Loperamide |
|
Formulary
|
Capsules 2mg First line |
 MHRA: Loperamide (Imodium): reports of serious cardiac adverse reactions with high doses of loperamide associated with abuse or misuse NICE: Short bowel syndrome |
|
| Teduglutide Revestive® |
|
Formulary
|
Injection Short bowel syndrome |
|
NICE TA804: Teduglutide for treating short bowel syndrome |
|
Links
LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway- LSCMMG: Primary Care Constipation Guidelines
- MHRA Drug Safety Update September 2017: Loperamide (Imodium): reports of serious cardiac adverse reactions with high doses of loperamide associated with abuse or misuse
- MHRA Drug Safety Update September 2017: Loperamide (Imodium): reports of serious cardiac adverse reactions with high doses of loperamide associated with abuse or misuse
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Loperamide (Imodium): reports of serious cardiac adverse reactions with high doses of loperamide associated with abuse or misuse
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE TA804: Teduglutide for treating short bowel syndrome
- NICE: Short bowel syndrome
- SPS: High dose loperamide use in high stoma output or short bowel syndrome
- SPS:High dose loperamide use in high stoma output or short bowel syndrome